Brit J Cancer:二甲双胍与肺癌患者生存率的关系

2020-12-02 MedSci原创 MedSci原创

二甲双胍可提高LC患者生存率,尤其是区域性SCC患者的LCSS。需要进一步的前瞻性研究来明确二甲双胍在LC治疗中的作用。

近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员旨在评估挪威全国范围内肺癌(LC)患者使用二甲双胍与患者生存之间的关联。

该研究将挪威处方数据库与2005-2014年期间挪威癌症登记处中诊断为LC的22324名患者联系起来。研究人员使用多变量时间固定和时间依赖性Cox回归估计了诊断前后二甲双胍的使用与患者总体生存期(OS)和LC特异性生存期(LCSS)之间的关联。

诊断前使用二甲双胍并不与所有患者的生存改善相关。尽管如此,在鳞状细胞癌(SCC)患者(风险比(HR)=0.79; 95%置信区间(CI)为0.62-0.99)和区域性SCC患者(HR=0.67; 95%CI为0.47-0.95)中,诊断前使用二甲双胍与更好的LCSS相关。诊断后二甲双胍的使用与所有患者(HR=0.83;95%CI为0.73-0.95)、SCC患者(HR=0.75;95%CI为0.57-0.98)、区域性LC(HR=0.74; 95%CI为0.59-0.94)和区域性SCC(HR=0.57;95%CI为0.38-0.86)LCSS改善相关。OS得到了类似的结果。累积使用分析发现,所有患者、腺癌和SCC患者以及区域性和转移性LC患者之间均存在剂量反应关系。

由此可见,使用二甲双胍可提高LC患者生存率,尤其是区域性SCC患者的LCSS。需要进一步的前瞻性研究来明确二甲双胍在LC治疗中的作用。

原始出处:

Suzan Brancher.et al.Metformin use and lung cancer survival: a population-based study in Norway.British Journal of Cancer.2020.https://www.nature.com/articles/s41416-020-01186-9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2021-02-01 6322400001

    神药

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-04 ms6000001547768209

    二甲双胍作用真多😄

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-03 BJying

    #二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-03 ms1000000951314514

    二甲双胍又刷新了我的认识

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-02 Baodongxu

    二甲双胍:见证奇迹的时刻又来了。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-02 lixiangyin5101_17573246

    需要进一步研究

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Aug 15 01:48:31 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932686, encodeId=204a1932686b9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu May 06 20:48:31 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921954, encodeId=14ec921954bc, content=神药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 01 15:39:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904975, encodeId=c1449049e56f, content=二甲双胍作用真多😄, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d025441508, createdName=ms6000001547768209, createdTime=Fri Dec 04 21:18:26 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256796, encodeId=4df21256e9623, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 04 03:48:31 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904532, encodeId=1a3490453265, content=#二甲双胍 #肺癌 二甲双胍可提高肺癌患者生存率,从此“神”上新高度, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/a16c22989a2247c0a54b44d3e3acdaaa/44abb281938b4e04bc086f8345254626.jpg, createdBy=fb825296401, createdName=BJying, createdTime=Thu Dec 03 10:58:36 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904516, encodeId=def9904516f7, content=二甲双胍又刷新了我的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/c03c19b3e5014508a69c98db1e6800b2/9488ac933bd44738b916807669473da4.jpg, createdBy=9e975440754, createdName=ms1000000951314514, createdTime=Thu Dec 03 10:24:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904398, encodeId=61fd904398b4, content=二甲双胍:见证奇迹的时刻又来了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Wed Dec 02 21:23:09 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904394, encodeId=ee0a90439431, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201202/13cd4d4e7ba441828e6c52e1b620d027/a7514941584a4656961851bd67ef4fbd.jpg, createdBy=19ee2419640, createdName=lixiangyin5101_17573246, createdTime=Wed Dec 02 21:14:13 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904357, encodeId=808290435e31, content=神药二甲双胍, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662490393, createdName=gaoyiling, createdTime=Wed Dec 02 17:11:49 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-02 gaoyiling

    神药二甲双胍

    0

相关资讯

ESMO:50%晚期NSCLC患者可获长达4年生存期 度伐利尤单抗治疗显优异生存获益

肺癌是男性和女性癌症死亡的主要原因,约占所有癌症死亡人数的五分之一。通常,肺癌分为非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC);其中大约85%被认定为非小细胞肺癌,15%为小细胞肺癌。

Eur J Heart Fail:肺癌、结肠癌或胰腺癌患者室性心动过速、室性早搏和死亡率的关系

结直肠癌、胰腺癌和非小细胞肺癌患者,非持续性室性心动过速更为常见,并且与PVC一起可预测长期死亡率。这提高了心血管死亡率成为某些癌症未来治疗干预目标的可能性。

Thorax:遗传引起的血清胆红素水平升高与肺癌发病率

遗传引起的血清胆红素升高在人群中普遍存在,可以保护暴露于高水平烟雾氧化剂的人群免受肺癌的侵害。

NEJM: 提前2年揭盲!吴一龙联合全球和国内284个中心团队,发现手术+精准分型靶向治疗降低早中期肺癌术后83%复发风险

在我国,肺癌年度发病人数高达78.4万,肺癌的发病率及死亡率分别占全部恶性肿瘤的20.03% 及26.99%,居恶性肿瘤之首。这使得肺癌治疗科研成果万众瞩目。

Chest:每年吸烟包数随机测量误差对肺癌筛查决策的影响

在决定是否进行CT筛查时,如果使用吸烟数量≥30包/年的标准,那么每年吸烟数量评估的随机误差会导致大量的患者被错误分类。但是,如果使用肺癌风险阈值则可以减少不可靠吸烟包数信息的影响。

JTO:阿司匹林、他汀类药物和二甲双胍与肺癌风险和相关死亡率的关系

本研究的目的是使用基于人群的全国队列数据研究阿司匹林,二甲双胍和他汀类药物与肺癌风险和死亡率的关系。